Theranos is now "on life support"; we make sense of the state of innovation of blood diagnostics

February 17, 2017 | Analyst Insight

It was back in June of 2016 when Forbes had revised its valuation of Theranos from $4.5 billion to $0 following a series of investigations and allegations that the company's blood...